A 90-day oral toxicity study in rats established a no-observed-adverse-effect level (NOAEL) of 460 mg/kg/day for males and 230 mg/kg/day for females, with most changes reversing after a 35-day recovery period.
Regulatory scientists, CBD product manufacturers, toxicologists, and food safety professionals.
NOAEL: 460 mg/kg/day (males), 230 mg/kg/day (females) over 90 days
What the researchers found
CBD was tolerated up to 460 mg/kg/day in males over 90 days. Some non-adverse organ and tissue changes occurred, and all changes except those at the highest dose reversed during the 35-day recovery period. Prenatal screening showed reduced body weight at the highest dose but no malformations.
Why it matters
As CBD products proliferate in consumer markets, establishing formal safety limits through standard toxicology testing provides a scientific basis for regulatory decisions about acceptable doses.
The numbers in context
NOAEL: 460 mg/kg/day (males), 230 mg/kg/day (females). 14-day tolerance up to 460 mg/kg/day. 90-day study with 35-day off-dose recovery. Prenatal study showed reduced body weight at highest dose but no gross abnormalities.
How the study worked
Three toxicology experiments in Sprague-Dawley rats: prenatal development screening, 14-day sighting study, and OECD-compliant 90-day subchronic oral toxicity study with 35-day recovery period. Doses: 0, 30, 115, 230, and 460 mg/kg/day of CBD isolate.
What this study cannot tell us
Animal study with uncertain human translation. Used purified CBD isolate, not whole-plant extract. Standard safety factors (typically 100x) are applied when extrapolating animal NOAELs to human recommended doses. Sex differences in NOAEL suggest hormonal interactions not fully understood.
How to read the evidence
OECD-compliant toxicology study with multiple dose levels and recovery period. Standard regulatory evidence for safety assessment.
When this study was published
Published 2023.
The bigger picture
Consumer CBD products typically deliver doses far below these NOAELs, even when accounting for body weight differences between rats and humans. However, rat toxicology data requires safety factors before translating to human recommendations.
Questions still open
- Why do female rats show lower NOAEL than males? Would whole-plant extracts containing other cannabinoids produce different toxicity profiles? How do these NOAELs translate to human equivalent doses?
Common questions
How much CBD is safe?
What happened to the rats at high CBD doses?
Read the original research
Subchronic oral toxicity assessment of a cannabis extract.
Regulatory toxicology and pharmacology : RTP, 144, 105496
Citation
Tallon, Mark J; Child, Robert. (2023). Subchronic oral toxicity assessment of a cannabis extract.. Regulatory toxicology and pharmacology : RTP, 144, 105496. https://doi.org/10.1016/j.yrtph.2023.105496
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk